Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

Helena Hohtari; Niels Pallisgaard; Matti Kankainen; Pekka Ellonen; Oscar Brück; Timo Siitonen; Marjaana Säily; Marjatta Sinisalo; Marja Pyörälä; Maija Itälä-Remes; Perttu Koskenvesa; Erkki Elonen; Satu Mustjoki; Kimmo Porkka

doi:10.3324/haematol.2021.280578

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

Helena Hohtari, Niels Pallisgaard, Matti Kankainen, Pekka Ellonen, Oscar Brück, Timo Siitonen, Marjaana Säily, Marjatta Sinisalo, Marja Pyörälä, Maija Itälä-Remes, Perttu Koskenvesa, Erkki Elonen, Satu Mustjoki, Kimmo Porkka

Forskningsoutput: Tidskriftsbidrag › Brev › Vetenskaplig

Originalspråk	engelska
Tidskrift	Haematologica
Volym	107
Nummer	8
Sidor (från-till)	1971-1976
Antal sidor	6
ISSN	0390-6078
DOI	https://doi.org/10.3324/haematol.2021.280578
Status	Publicerad - aug. 2022
MoE-publikationstyp	B1 Artikel i en vetenskaplig tidskrift

Vetenskapsgrenar

3111 Biomedicinska vetenskaper
3122 Cancersjukdomar

Åtkomst av dokument

10.3324/haematol.2021.280578

10625-Article Text-78144-2-10-20220728Slutlig publicerad version, 627 KBLicens: CC BY-NC

Citera det här

Hohtari, H., Pallisgaard, N., Kankainen, M., Ellonen, P., Brück, O., Siitonen, T., Säily, M., Sinisalo, M., Pyörälä, M., Itälä-Remes, M., Koskenvesa, P., Elonen, E., Mustjoki, S., & Porkka, K. (2022). Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 107(8), 1971-1976. https://doi.org/10.3324/haematol.2021.280578

@article{98aae1ee6ef44dbc84b2e7f61422702e,

title = "Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia",

keywords = "3111 Biomedicine, 3122 Cancers",

author = "Helena Hohtari and Niels Pallisgaard and Matti Kankainen and Pekka Ellonen and Oscar Br{\"u}ck and Timo Siitonen and Marjaana S{\"a}ily and Marjatta Sinisalo and Marja Py{\"o}r{\"a}l{\"a} and Maija It{\"a}l{\"a}-Remes and Perttu Koskenvesa and Erkki Elonen and Satu Mustjoki and Kimmo Porkka",

note = "Funding Information: NGS library preparation, sequencing and sequence analysis were performed by the Institute for Molecular Medicine Finland (FIMM) Technology Center, University of Helsinki. We thank laboratory technicians Jay Klievink in Hematology Research Unit Helsinki (HRUH) and Minna Suvela in FIMM for technical support with the DNA extractions and laboratory coordinator Minna Tuominen in FIMM for technical support with multiplex ligation-dependent probe amplification. We are grateful to the members of the HRUH for discussions and technical help. We thank research nurses Anne Gesterberg, Jenni Raali and Susanna Helkkula for help with clinical data. We thank Dr Veli Kairisto in Tykslab, Dr Taru Kuittinen in Kuopio University Hospital and clinical laboratory geneticists Anne Juvonen and Tarja Salonen in HUSLAB for help with clinical samples. The samples of this project were provided by Finnish University Hospital clinical laboratories and the Finnish Hematology Registry and Clinical Biobank (FHRB) with appropriate ethics approval (Dnro 202/06.01.00/2013). We thank all the patients for their generous participation. The FHRB Biobank is supported by the Finnish Association of Hematology, the Finnish Red Cross Blood Service, Institute for Molecular Medicine Finland, and the participating hospitals in Finland. This study was supported by the Doctoral Program in Clinical Research at the University of Helsinki and personal grants (to HH) from Emil Aaltonen Foundation, Ida Montin Foundation, Blood Disease Research Foundation, Finnish Hematology Association, Finnish Medical Foundation, Biomedicum Helsinki Foundation, Paulo Foundation, (to SM) Finnish Cancer Organizations, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Relander Foundation, and state funding for university-level health research in Finland. The laboratory analytics costs of this study were funded by Incyte. Funding Information: TS (not related to this study) is a member of the advisory board of Celgene and AbbVie; is a member of the advisory board of and received lecture fees from Pfizer and Janssen-Cilag; received lecture fees from Bristol Myers Squibb; received congress fees from and is a member of the advisory board of Novartis; received congress fees from Amgen. MP (not-related to this study) is a member of the advisory board of Pfizer and AbbVie; received lecture and congress fees from Novartis. OB received consultancy fees from Novartis and Sanofi. SM (not related to this study) received research funding from Novartis, BMS, Janpix, and Pfizer. All other authors have no conflicts of interest to disclose. Funding Information: NGS library preparation, sequencing and sequence analysis were performed by the Institute for Molecular Medicine Finland (FIMM) Technology Center, University of Helsinki. We thank laboratory technicians Jay Klievink in Hematology Research Unit Helsinki (HRUH) and Minna Suvela in FIMM for technical support with the DNA extractions and laboratory coordinator Minna Tuominen in FIMM for technical support with multiplex ligation-dependent probe amplification. We are grateful to the members of the HRUH for discussions and technical help. We thank research nurses Anne Gesterberg, Jenni Raali and Susanna Helkkula for help with clinical data. We thank Dr Veli Kairisto in Tykslab, Dr Taru Kuittinen in Kuopio University Hospital and clinical laboratory geneticists Anne Juvonen and Tarja Salonen in HUSLAB for help with clinical samples. The samples of this project were provided by Finnish University Hospital clinical laboratories and the Finnish Hematology Registry and Clinical Biobank (FHRB) with appropriate ethics approval (Dnro 202/06.01.00/2013). We thank all the patients for their generous participation. The FHRB Biobank is supported by the Finnish Association of Hematology, the Finnish Red Cross Blood Service, Institute for Molecular Medicine Finland, and the participating hospitals in Finland.",

year = "2022",

month = aug,

doi = "10.3324/haematol.2021.280578",

language = "English",

volume = "107",

pages = "1971--1976",

journal = "Haematologica",

issn = "0390-6078",

publisher = "FERRATA STORTI FOUNDATION",

number = "8",

}

Hohtari, H, Pallisgaard, N, Kankainen, M, Ellonen, P, Brück, O, Siitonen, T, Säily, M, Sinisalo, M, Pyörälä, M, Itälä-Remes, M, Koskenvesa, P , Elonen, E , Mustjoki, S & Porkka, K 2022, 'Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia', Haematologica, vol. 107, nr. 8, s. 1971-1976. https://doi.org/10.3324/haematol.2021.280578

TY - JOUR

T1 - Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

AU - Hohtari, Helena

AU - Pallisgaard, Niels

AU - Kankainen, Matti

AU - Ellonen, Pekka

AU - Brück, Oscar

AU - Siitonen, Timo

AU - Säily, Marjaana

AU - Sinisalo, Marjatta

AU - Pyörälä, Marja

AU - Itälä-Remes, Maija

AU - Koskenvesa, Perttu

AU - Elonen, Erkki

AU - Mustjoki, Satu

AU - Porkka, Kimmo

N1 - Funding Information: NGS library preparation, sequencing and sequence analysis were performed by the Institute for Molecular Medicine Finland (FIMM) Technology Center, University of Helsinki. We thank laboratory technicians Jay Klievink in Hematology Research Unit Helsinki (HRUH) and Minna Suvela in FIMM for technical support with the DNA extractions and laboratory coordinator Minna Tuominen in FIMM for technical support with multiplex ligation-dependent probe amplification. We are grateful to the members of the HRUH for discussions and technical help. We thank research nurses Anne Gesterberg, Jenni Raali and Susanna Helkkula for help with clinical data. We thank Dr Veli Kairisto in Tykslab, Dr Taru Kuittinen in Kuopio University Hospital and clinical laboratory geneticists Anne Juvonen and Tarja Salonen in HUSLAB for help with clinical samples. The samples of this project were provided by Finnish University Hospital clinical laboratories and the Finnish Hematology Registry and Clinical Biobank (FHRB) with appropriate ethics approval (Dnro 202/06.01.00/2013). We thank all the patients for their generous participation. The FHRB Biobank is supported by the Finnish Association of Hematology, the Finnish Red Cross Blood Service, Institute for Molecular Medicine Finland, and the participating hospitals in Finland. This study was supported by the Doctoral Program in Clinical Research at the University of Helsinki and personal grants (to HH) from Emil Aaltonen Foundation, Ida Montin Foundation, Blood Disease Research Foundation, Finnish Hematology Association, Finnish Medical Foundation, Biomedicum Helsinki Foundation, Paulo Foundation, (to SM) Finnish Cancer Organizations, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Relander Foundation, and state funding for university-level health research in Finland. The laboratory analytics costs of this study were funded by Incyte. Funding Information: TS (not related to this study) is a member of the advisory board of Celgene and AbbVie; is a member of the advisory board of and received lecture fees from Pfizer and Janssen-Cilag; received lecture fees from Bristol Myers Squibb; received congress fees from and is a member of the advisory board of Novartis; received congress fees from Amgen. MP (not-related to this study) is a member of the advisory board of Pfizer and AbbVie; received lecture and congress fees from Novartis. OB received consultancy fees from Novartis and Sanofi. SM (not related to this study) received research funding from Novartis, BMS, Janpix, and Pfizer. All other authors have no conflicts of interest to disclose. Funding Information: NGS library preparation, sequencing and sequence analysis were performed by the Institute for Molecular Medicine Finland (FIMM) Technology Center, University of Helsinki. We thank laboratory technicians Jay Klievink in Hematology Research Unit Helsinki (HRUH) and Minna Suvela in FIMM for technical support with the DNA extractions and laboratory coordinator Minna Tuominen in FIMM for technical support with multiplex ligation-dependent probe amplification. We are grateful to the members of the HRUH for discussions and technical help. We thank research nurses Anne Gesterberg, Jenni Raali and Susanna Helkkula for help with clinical data. We thank Dr Veli Kairisto in Tykslab, Dr Taru Kuittinen in Kuopio University Hospital and clinical laboratory geneticists Anne Juvonen and Tarja Salonen in HUSLAB for help with clinical samples. The samples of this project were provided by Finnish University Hospital clinical laboratories and the Finnish Hematology Registry and Clinical Biobank (FHRB) with appropriate ethics approval (Dnro 202/06.01.00/2013). We thank all the patients for their generous participation. The FHRB Biobank is supported by the Finnish Association of Hematology, the Finnish Red Cross Blood Service, Institute for Molecular Medicine Finland, and the participating hospitals in Finland.

PY - 2022/8

Y1 - 2022/8

KW - 3111 Biomedicine

KW - 3122 Cancers

U2 - 10.3324/haematol.2021.280578

DO - 10.3324/haematol.2021.280578

M3 - Letter

C2 - 35484650

AN - SCOPUS:85135419364

VL - 107

SP - 1971

EP - 1976

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -